Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Naunyn-Schmiedeberg's Archives of Pharmacology

• Publication date

  2024-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00210-024-03443-7PMID 39316087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance

  2024cited by this paper
• Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.

  2024cited by this paper
• Lactylome Analysis Unveils Lactylation‐Dependent Mechanisms of Stemness Remodeling in the Liver Cancer Stem Cells

  2024cited by this paper
• Multifaceted Carbonized Metal-Organic Frameworks Synergize with Immune Checkpoint Inhibitors for Precision and Augmented Cuproptosis Cancer Therapy.

  2024cited by this paper
• T Cell Exhaustion.

  2024cited by this paper
• Heterogeneity‐induced NGF‐NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti‐tumor immunotherapy with PD‐1 mAb in hepatocellular carcinoma

  2024cited by this paper
• Tyrosine kinase signaling-independent MET-targeting with CAR-T cells

  2023cited by this paper
• Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma

  2023cited by this paper
• From bench to bedside: the history and progress of CAR T cell therapy

  2023cited by this paper
• Development of Engineered CAR T Cells Targeting Tumor-Associated Glycoforms of MUC1 for the Treatment of Intrahepatic Cholangiocarcinoma

  2023cited by this paper
• Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC

  2023influential reference
• The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

  2023cited by this paper
• Metabolic challenges and interventions in CAR T cell therapy

  2023cited by this paper
• Human Placental Mesenchymal Stem Cell-derived Exosomes in Combination with Hyperbaric Oxygen Synergistically Promote Recovery after Spinal Cord Injury in Rats

  2023cited by this paper
• The roles and mechanism of m6A RNA methylation regulators in cancer immunity.

  2023cited by this paper
• RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

  2023cited by this paper
• The SNHG1-Centered ceRNA Network Regulates Cell Cycle and Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma.

  2022cited by this paper
• MicroRNAs-mediated regulation pathways in rheumatic diseases

  2022cited by this paper
• Atorvastatin Rapidly Reduces Hepatitis B Viral Load in Combination with Tenofovir: A Prospective Clinical Trial

  2022cited by this paper
• Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

  2022influential reference
• Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

  2022cited by this paper
• Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma

  2022cited by this paper
• Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer

  2022cited by this paper
• Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

  2021cited by this paper
• The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021influential reference
• The evolving landscape of immunotherapy in solid tumors

  2021cited by this paper
• c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo

  2021cited by this paper
• TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy

  2021cited by this paper
• Immunotherapies for hepatocellular carcinoma

  2021cited by this paper
• Nanoscale covalent organic frameworks: from controlled synthesis to cancer therapy.

  2021cited by this paper
• Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

  2021cited by this paper
• A summary of current NKG2D-based CAR clinical trials

  2021cited by this paper
• Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma

  2021cited by this paper
• IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

  2021cited by this paper
• CAR-T cell therapy: current limitations and potential strategies

  2021cited by this paper
• Cancer statistics for the year 2020: An overview

  2021influential reference
• Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma

  2021cited by this paper
• Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

  2021cited by this paper
• Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives

  2020cited by this paper
• Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

  2020cited by this paper
• Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.

  2020cited by this paper
• CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma

  2020cited by this paper
• New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma

  2020influential reference
• Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment

  2020cited by this paper
• The role of alpha-fetoprotein in hepatocellular carcinoma drug resistance.

  2020cited by this paper
• Recent advances in CAR-T cell engineering

  2020cited by this paper
• Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma

  2020cited by this paper
• Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial

  2020cited by this paper
• The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future

  2020cited by this paper
• The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.

  2019cited by this paper
• Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy

  2019cited by this paper
• Tumour evolution in hepatocellular carcinoma

  2019cited by this paper
• Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells

  2019cited by this paper
• Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression.

  2019cited by this paper
• Engineering strategies to overcome the current roadblocks in CAR T cell therapy

  2019cited by this paper
• A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma.

  2019cited by this paper
• Preclinical Evaluation of Chimeric Antigen Receptor–Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer

  2019cited by this paper
• Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations

  2019cited by this paper
• The making and function of CAR cells

  2019cited by this paper
• Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells

  2019cited by this paper
• Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

  2018influential reference
• The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis.

  2018cited by this paper
• The immunology of hepatocellular carcinoma

  2018cited by this paper
• Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

  2018cited by this paper
• Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

  2018cited by this paper
• TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function

  2018cited by this paper
• AASLD guidelines for the treatment of hepatocellular carcinoma

  2018cited by this paper
• Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein

  2018cited by this paper
• Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

  2018cited by this paper
• Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

  2018cited by this paper
• In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

  2018cited by this paper
• Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

  2018cited by this paper
• Teaching an old dog new tricks: next-generation CAR T cells

  2018cited by this paper
• Chimeric antigen receptor T-cell therapies for lymphoma

  2018influential reference
• CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

  2018cited by this paper
• A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

  2017cited by this paper
• Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

  2017cited by this paper
• Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma

  2017cited by this paper
• Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.

  2017cited by this paper
• Engineering CAR-T cells

  2017cited by this paper
• The Principles of Engineering Immune Cells to Treat Cancer.

  2017cited by this paper
• A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

  2017cited by this paper
• Programmed cell death and the immune system

  2017cited by this paper
• CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity

  2017influential reference
• Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization

  2016cited by this paper
• Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity

  2016cited by this paper
• Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

  2016cited by this paper
• Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

  2016cited by this paper
• Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.

  2016cited by this paper
• CD133, Selectively Targeting the Root of Cancer

  2016cited by this paper
• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

  2016cited by this paper
• Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.

  2016cited by this paper
• Designing chimeric antigen receptors to effectively and safely target tumors.

  2015cited by this paper
• Bladder Management With Epidural Anesthesia During Labor: A Randomized Controlled Trial

  2015cited by this paper
• Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions

  2015cited by this paper
• Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes

  2015cited by this paper
• Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

  2015cited by this paper
• Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

  2015cited by this paper
• Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

  2015cited by this paper

• Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy.

  2026cites this paper
• Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates

  2025cites this paper
• Targeting hepatocellular carcinoma：molecular mechanisms and clinical studies.

  2025cites this paper
• Nanomaterials Mediated Enhancement of CAR-T for HCC: Revolutionizing Immunotherapy Strategies

  2025influential citation
• Adoptive cell therapy for HBV-associated liver diseases

  2025cites this paper
• Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients.

  2025cites this paper
• Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade

  2025cites this paper